EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a translatable gene augmentation therapy for CNGB1-retinitis pigmentosa

Laurence M Occelli, Lena Zobel, Jonathan Stoddard, Johanna Wagner, Nathaniel Pasmanter, Janice Querubin, Lauren M Renner, Rene Reynaga, Paige A Winkler, Kelian Sun, Luis Felipe L P Marinho, Catherine R O'Riordan und 8 weitere

Molecular Therapy · 2023

DOI: 10.1016/j.ymthe.2023.04.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2023. Verfasst von Laurence M Occelli und 19 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, Michigan State University, 736 Wilson Road, East Lansing, MI 48864, USA. Hauptthemen laut MEDLINE: Retinitis Pigmentosa, Parvovirinae. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NEI NIH HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we investigate a gene augmentation therapy candidate for the treatment of retinitis pigmentosa (RP) due to cyclic nucleotide-gated channel beta 1 (CNGB1) mutations. We use an adeno-associated virus serotype 5 with transgene under control of a novel short human rhodopsin promoter. The promoter/capsid combination drives efficient expression of a reporter gene (AAV5-RHO-eGFP) exclusively in rod photoreceptors in primate, dog, and mouse following subretinal delivery. The therapeutic vector (AAV5-RHO-CNGB1) delivered to the subretinal space of CNGB1 mutant dogs restores rod-mediated retinal function (electroretinographic responses and vision) for at least 12 months post treatment. Immunohistochemistry shows human CNGB1 is expressed in rod photoreceptors in the treated regions as well as restoration of expression and trafficking of the endogenous alpha subunit of the rod CNG channel required for normal channel formation. The treatment reverses abnormal accumulation of the second messenger, cyclic guanosine monophosphate, which occurs in rod photoreceptors of CNGB1 mutant dogs, confirming formation of a functional CNG channel. In vivo imaging shows long-term preservation of retinal structure. In conclusion, this study establishes the long-term efficacy of subretinal delivery of AAV5-RHO-CNGB1 to rescue the disease phenotype in a canine model of CNGB1-RP, confirming its suitability for future clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinitis PigmentosaParvovirinaeCyclic Nucleotide-Gated Cation ChannelsRetinaHumansDependovirusMiceRhodopsinDogsAnimalsElectroretinography

Stichwörter der Autor:innen

CNGB1adeno-associated virusdogelectroretinographygene therapynonhuman primateperifoveal chorioretinal atrophyretinitis pigmentosashort rhodopsin promoterspectral domain optical coherence tomography

Substanzen

Cyclic Nucleotide-Gated Cation ChannelsRhodopsinCNGB1 protein, human

Autor:innen und Institutionen

  • College of Veterinary Medicine, Michigan State University, 736 Wilson Road, East Lansing, MI 48864, USA.
  • Department of Pharmacy-Center for Drug Research, Ludwig-Maximilians-Universität München, 81377 Munich, Germany; Department of Ophthalmology, University Hospital, LMU Munich, 80336 Munich, Germany.
  • Oregon National Primate Research Center, Oregon Health & Science University, 505 NW 185(th) Avenue, Beaverton, OR 97005, USA.
  • Department of Pharmacy-Center for Drug Research, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.
  • Genomic Medicine Unit, Sanofi, 225 Second Avenue, Waltham, MA 02451, USA.
  • Casey Eye Institute, Oregon Health & Science University, 515 Campus Drive, Portland, OR 97239, USA.

Förderung

  • NIH HHS
  • NEI NIH HHS
  • NCRR NIH HHS
  • Oregon National Primate Research Center
  • National Institutes of Health
  • University of Utah

Zitieren

APA

Occelli, L. M., Zobel, L., Stoddard, J., Wagner, J., Pasmanter, N., Querubin, J., Renner, L. M., Reynaga, R., Winkler, P. A., Sun, K., Marinho, L. F. L. P., O'Riordan, C. R., Frederick, A., Lauer, A., Tsang, S. H., Hauswirth, W. W., McGill, T. J., Neuringer, M., Michalakis, S., & Petersen-Jones, S. M. (2023). Development of a translatable gene augmentation therapy for CNGB1-retinitis pigmentosa. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2023.04.005

Vancouver

Occelli LM, Zobel L, Stoddard J, Wagner J, Pasmanter N, Querubin J, et al. Development of a translatable gene augmentation therapy for CNGB1-retinitis pigmentosa. Molecular Therapy. 2023. doi:10.1016/j.ymthe.2023.04.005

BibTeX
@article{Occelli2023,
  author = {Occelli, Laurence M and Zobel, Lena and Stoddard, Jonathan and Wagner, Johanna and Pasmanter, Nathaniel and Querubin, Janice and Renner, Lauren M and Reynaga, Rene and Winkler, Paige A and Sun, Kelian and Marinho, Luis Felipe L P and O'Riordan, Catherine R and Frederick, Amy and Lauer, Andreas and Tsang, Stephen H and Hauswirth, William W and McGill, Trevor J and Neuringer, Martha and Michalakis, Stylianos and Petersen-Jones, Simon M},
  title = {Development of a translatable gene augmentation therapy for CNGB1-retinitis pigmentosa},
  journal = {Molecular Therapy},
  year = {2023},
  doi = {10.1016/j.ymthe.2023.04.005}
}
Kostenlos starten →